Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis

The real‐world of hospital mortality for liver cirrhosis inpatients in Japan: a large‐scale cohort study using a medical claims database

(2021) Hiroshi Yatsuhashi et al.   HEPATOLOGY RESEARCH

Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study

(2021) Shunichiro Fujiyama et al.   BMC GASTROENTEROLOGY

Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus

(2021) Takashi Kumada et al.   Infectious Diseases and Therapy

Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

(2021) Toshifumi Tada et al.   JOURNAL OF MEDICAL VIROLOGY

The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study

(2020) Akito Nozaki et al.   Hepatology International

Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update

(2020)   HEPATOLOGY RESEARCH

Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis

(2020) Kazuki Ohya et al.   HEPATOLOGY RESEARCH

Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection

(2020) Yoshinari Takaoka et al.   HEPATOLOGY RESEARCH

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

(2020) Yuki Tahata et al.   JOURNAL OF GASTROENTEROLOGY

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study

(2020) Masanori Atsukawa et al.   Infectious Diseases and Therapy

The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study

(2019) Masanori Atsukawa et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan

(2019) Hidenori Toyoda et al.   Open Forum Infectious Diseases

Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents

(2019) Fasiha Kanwal et al.   HEPATOLOGY

Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

(2019) Shohei Tsuji et al.   HEPATOLOGY RESEARCH

Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema

(2019) Masanori Atsukawa et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection

(2018) Omar El-Sherif et al.   GASTROENTEROLOGY

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

(2018) Vincenza Calvaruso et al.   GASTROENTEROLOGY

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

(2018) Tetsuo Takehara et al.   JOURNAL OF GASTROENTEROLOGY

What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?

(2018) George N. Ioannou et al.   GASTROENTEROLOGY

Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments

(2017) Javier Mar et al.   Expert Review of Gastroenterology & Hepatology

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function

(2017) Atsushi Hiraoka et al.   Liver Cancer

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

(2016) Masao Omata et al.   Hepatology International

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

(2016) Graham R. Foster et al.   JOURNAL OF HEPATOLOGY

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

(2016) Michelle C.M. Cheung et al.   JOURNAL OF HEPATOLOGY

Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies

(2015) K. Deterding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database

(2015) David E. Kaplan et al.   Clinical Gastroenterology and Hepatology

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

(2015)   HEPATOLOGY

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

(2015) Michael P. Curry et al.   NEW ENGLAND JOURNAL OF MEDICINE